摘要
Poly(ADP-ribose)polymerase inhibitors(PARPi)are a new class of agents with unparalleled clinical achievement for driving synthetic lethality in BRCA-deficient cancers.Recent FDA approval of PARPi has motivated clinical trials centered around the optimization of PARPi-associated therapies in a variety of BRCA-deficient cancers.This review highlights recent advancements in understanding the molecular mechanisms of PARP‘trapping’and synthetic lethality.Particular attention is placed on the potential extension of PARPi therapies from BRCA-deficient patients to populations with other homologous recombination-deficient backgrounds,and common characteristics of PARPi and non-homologous end-joining have been elucidated.The synergistic antitumor effect of combining PARPi with various immune checkpoint blockades has been explored to evaluate the potential of combination therapy in attaining greater therapeutic outcome.This has shed light onto the differing classifications of PARPi as well as the factors that result in altered PARPi activity.Lastly,acquired chemoresistance is a crucial issue for clinical application of PARPi.The molecularmechanisms underlying PARPi resistance and potential overcoming strategies are discussed.
基金
This work was supported by the National Cancer Institute,the National Institutes of Health(Grant No.R01CA236878).
